Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

Health Economics

Volumn 11, Issue 3, 2002, Pages 233-248

  Neymark, N ^a   Adriaenssen, I ^a   Gorlia, T ^a   Caleo, S ^a   Bolla, M ^b  

^a EORTC DATA CENTER   (Belgium)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Censoring; Cost effectiveness analysis; Estimation of mean survival time; Locally advanced prostate cancer; Survival data

Indexed keywords

CYPROTERONE ACETATE; ESTRAMUSTINE; FLUOROURACIL; FLUTAMIDE; FOLINIC ACID; GOSERELIN; LEUPRORELIN; NILUTAMIDE; TRIPTORELIN;

ADVANCED CANCER; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FRANCE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DRUG COSTS; FRANCE; GOSERELIN; HEALTH CARE COSTS; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036208302     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.662     Document Type: Article

References (38)

1. Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU
2. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer
3. How should cost data in pragmatic randomised trials be analysed?
4. The distribution of health care costs and their statistical analysis for economic evaluation
5. A comparison of several methods of estimating the survival function when there is extreme right censoring
6. Weighted Kaplan-Meier statistics: A class of distance tests for censored survival data
7. Gain in life expectancy from medical interventions - Standardizing data on outcomes
8. The standard error of an estimate of expectational life
9. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups - Interpretation and power considerations
10. The challenge of locally advanced prostate cancer
11. Update on the treatment of prostate cancer with external beam irradiation
12. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
13. Guide Pratique des Médicaments
14. Nomenclature Générale des Actes Professionels
15. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II: Analysis and examples
16. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
17. Survival curve fitting using the Gompertz function: A methodology for conducting cost-effectiveness analysis on mortality data
18. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy for high-risk resected cutaneous melanoma
19. Maximum-likelihood estimation of the parameters of the Gompertz survival function
20. Parametric versus non-parametric methods for estimating cure rates based on censored survival data
21. Estimating medical costs from incomplete follow-up data
22. Constructing confidence intervals for cost-effectiveness ratios: An evaluation of parametric and non-parametric techniques using Monte Carlo simulation
23. Bayesian estimation of cost-effectiveness ratios from clinical trials
24. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane
25. A Bayesian approach to stochastic cost-effectiveness analysis
26. When do the "dollars" make sense? Towards a conceptual framework for contingent valuation studies in health care
27. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy
28. Quality adjusted survival analysis with repeated quality of life measures
29. A comparison of methods for accounting for truncated trials of lifetime therapies
30. A regression-based method for estimating mean treatment cost in the presence of right-censoring
31. Estimating medical costs when follow-up is incomplete and data are missing at random